Advertisement

Preoperation Chemotherapy

  • Massimo Aglietta

Abstract

Oxaliplatin and irinotecan have widened the chemotherapy alternatives available to patients with metastatic colorectal cancer, and effective targeted agents have further improved treatment efficacy. Combinations of these drugs have set a new benchmark of survival at ∼20 months, enabling a substantial number of patients who were not candidates for resection to qualify for the procedure. Liver resection after tumor downsizing has yielded encouraging results, although cure is rarely achieved. Based on several theoretical advantages, preoperative chemotherapy is increasingly being used also in patients with resectable disease. However, the debate is still ongoing especially with respect to the oncologic benefits and the numerous drawbacks, including hepatic toxicity and the risk of inducing a complete radiologic response.

Keywords

Epidermal Growth Factor Receptor Liver Metastasis Clin Oncol Hepatic Resection Preoperative Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914CrossRefPubMedGoogle Scholar
  2. 2.
    Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041–1047CrossRefPubMedGoogle Scholar
  3. 3.
    Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMedGoogle Scholar
  4. 4.
    Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMedGoogle Scholar
  5. 5.
    Kohne CH, van Cutsem E, Wils J et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856–4865CrossRefPubMedGoogle Scholar
  6. 6.
    Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147PubMedGoogle Scholar
  7. 7.
    Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214CrossRefPubMedGoogle Scholar
  8. 8.
    Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676CrossRefPubMedGoogle Scholar
  9. 9.
    Arkenau HT, Arnold D, Cassidy J et al (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 26:5910–5917CrossRefPubMedGoogle Scholar
  10. 10.
    Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311–1319CrossRefPubMedGoogle Scholar
  11. 11.
    Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMedGoogle Scholar
  12. 12.
    Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–667CrossRefPubMedGoogle Scholar
  13. 13.
    Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47CrossRefPubMedGoogle Scholar
  14. 14.
    Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMedGoogle Scholar
  15. 15.
    Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefPubMedGoogle Scholar
  16. 16.
    Wong R, Saffery C, Barbachano Y et al (2009) BOXER: A multicenter phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. Eur J Cancer 7(suppl):6076Google Scholar
  17. 17.
    Masi G, Vasile E, Loupakis F et al (2009) Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II study by the G.O.N.O. group. Ann Oncol 20 (Suppl 7)Google Scholar
  18. 18.
    Cohen AD, Kemeny NE (2003) An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8:553–566CrossRefPubMedGoogle Scholar
  19. 19.
    Barber FD, Mavligit G, Kurzrock R (2004) Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 30:425–436CrossRefPubMedGoogle Scholar
  20. 20.
    Meta-Analysis Group in Cancer (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Nat Cancer Inst 88:223–224CrossRefGoogle Scholar
  21. 21.
    Kerr DJ, McArdle CS, Ledermann J et al (2003) Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361:368–373CrossRefPubMedGoogle Scholar
  22. 22.
    Goere D, Deshaies I, de Baere T et al (2010) Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 251:686–691CrossRefPubMedGoogle Scholar
  23. 23.
    Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 10:663–669CrossRefPubMedGoogle Scholar
  24. 24.
    Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657CrossRefPubMedGoogle Scholar
  25. 25.
    Barone C, Nuzzo G, Cassano A et al (2007) Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97:1035–1039CrossRefPubMedGoogle Scholar
  26. 26.
    Alberts SR, Horvath WL, Maohoney MR et al (2005) Oxaliplatin, fluorouracil and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group (NCCTG) phase II study. J Clin Oncol 23:1–7CrossRefGoogle Scholar
  27. 27.
    Perez-Staub N, Lledo G, Paye F et al (2006) Surgery of colorectal metastasis in the Optimox 1 study. AGERCOR study. J Clin Oncol 24(18 suppl):3522Google Scholar
  28. 28.
    Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842–1847CrossRefPubMedGoogle Scholar
  29. 29.
    Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1–7CrossRefPubMedGoogle Scholar
  30. 30.
    Zorzi D, Kishi Y, Maru DM et al (2009) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases (abstract 295). American society of clinical oncology 2009 Gastrointestinal Cancers Symposium, January 15–17, 2009, San Francisco, CAGoogle Scholar
  31. 31.
    Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522CrossRefPubMedGoogle Scholar
  32. 32.
    Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657CrossRefPubMedGoogle Scholar
  33. 33.
    Rivoire M, De Cian F, Meeus P et al (2002) Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95:2283–2292CrossRefPubMedGoogle Scholar
  34. 34.
    Masi G, Cupini S, Marcucci L et al (2006) Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 13:58–65CrossRefPubMedGoogle Scholar
  35. 35.
    Capussotti L, Muratore M, Mulas MM et al (2006) Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 93:1001–1006CrossRefPubMedGoogle Scholar
  36. 36.
    Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835CrossRefPubMedGoogle Scholar
  37. 37.
    Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRefPubMedGoogle Scholar
  38. 38.
    Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy. A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1064CrossRefPubMedGoogle Scholar
  39. 39.
    Zakaria S, Donohue JH, Que FG et al (2007) Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 246:183–191CrossRefPubMedGoogle Scholar
  40. 40.
    Blazer DG III, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344–5351CrossRefPubMedGoogle Scholar
  41. 41.
    Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110:2761–2767CrossRefPubMedGoogle Scholar
  42. 42.
    Tanaka K, Adam R, Shimada H et al (2003) Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90:963–96CrossRefPubMedGoogle Scholar
  43. 43.
    Allen PJ, Kemeny N, Jarnagin W et al (2003) Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7:109–115CrossRefPubMedGoogle Scholar
  44. 44.
    Gruenberger B, Scheithauer W, Punzengruber R et al (2008) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120CrossRefPubMedGoogle Scholar
  45. 45.
    Chua TC, Saxena A, Liauw W et al (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17:492–501CrossRefPubMedGoogle Scholar
  46. 46.
    Tanaka K, Adam R, Shimada H et al (2003) Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90:963–969CrossRefPubMedGoogle Scholar
  47. 47.
    Allen PJ, Kemeny N, Jarnagin W et al (2003) Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7:109–115CrossRefPubMedGoogle Scholar
  48. 48.
    Capussotti L, Viganò L, Ferrero A et al (2007) Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 14:1143–1150CrossRefPubMedGoogle Scholar
  49. 49.
    Minagawa M, Yamamoto J, Miwa S et al (2006) Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg 141:1006–1012CrossRefPubMedGoogle Scholar
  50. 50.
    Reddy SK, Zorzi D, Lum YW et al (2009) Timing of Multimodality Therapy for Resectable Synchronous Colorectal Liver Metastases: A Retrospective Multi-Institutional Analysis. Ann Surg Oncol 16:1809–1819CrossRefPubMedGoogle Scholar
  51. 51.
    Adam R, Delvart V, Gorden L et al (in press) Is perioperative chemotherapy useful for metachronous solitary colorectal liver metastases? Ann SurgGoogle Scholar
  52. 52.
    Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072CrossRefPubMedGoogle Scholar
  53. 53.
    Kooby DA, Fong Y, Suriawinata A et al (2003) Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7:1034–44CrossRefPubMedGoogle Scholar
  54. 54.
    Behrns KE, Tsiotos GG, DeSouza NF et al (1998) Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2:292–298CrossRefPubMedGoogle Scholar
  55. 55.
    Belghiti J, Hiramatsu K, Benoist S et al (2000) Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191:38–46CrossRefPubMedGoogle Scholar
  56. 56.
    McCormack L, Petrowsky H, Jochum W et al (2007) Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: A matched case-control study. Ann Surg 245:923–930CrossRefPubMedGoogle Scholar
  57. 57.
    Fernandez FG, Ritter J, Goodwin JW et al (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845–853CrossRefPubMedGoogle Scholar
  58. 58.
    Sasaki M, Itatsu K, Minato H et al (2007) Flare-up of nonalcoholic steatohepatitis after hepatectomy resulted in hepatic failure in a patient with type 2 diabetes mellitus. Dig Dis Sci 52:3473–3476CrossRefPubMedGoogle Scholar
  59. 59.
    Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466CrossRefPubMedGoogle Scholar
  60. 60.
    Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304CrossRefPubMedGoogle Scholar
  61. 61.
    Pawlik TM, Olino K, Gleisner AL et al (2007) Preoperative chemotherapy for colorectal liver metastases: Impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860–868CrossRefPubMedGoogle Scholar
  62. 62.
    Kandutsch S, Klinger M, Hacker S et al (2008) Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 34:1231–1236PubMedGoogle Scholar
  63. 63.
    Rubbia-Brandt L, Lauwers GY, Wang H et al (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:430–439CrossRefPubMedGoogle Scholar
  64. 64.
    Overman MJ, Maru DM, Charnsangavej C et al (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:2549–2555CrossRefPubMedGoogle Scholar
  65. 65.
    Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983–4990CrossRefPubMedGoogle Scholar
  66. 66.
    Welsh FK, Tilney HS, Tekkis PP et al (2007) Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96:1037–1042CrossRefPubMedGoogle Scholar
  67. 67.
    Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124CrossRefPubMedGoogle Scholar
  68. 68.
    Mehta NN, Ravikumar R, Coldham CA et al (2008) Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 34:782–786PubMedGoogle Scholar
  69. 69.
    Masi G, Loupakis F, Pollina L et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249:420–425CrossRefPubMedGoogle Scholar
  70. 70.
    Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173–180CrossRefPubMedGoogle Scholar
  71. 71.
    Kesmodel SB, Ellis LM, Lin E et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 26:5254–5260CrossRefPubMedGoogle Scholar
  72. 72.
    D’Angelica M, Kornprat P, Gonen M et al (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 14:759–765CrossRefPubMedGoogle Scholar
  73. 73.
    Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106CrossRefPubMedGoogle Scholar
  74. 74.
    Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110:2761–2767CrossRefPubMedGoogle Scholar
  75. 75.
    Adam R, Aloia T, Levi F et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593–602CrossRefPubMedGoogle Scholar
  76. 76.
    Adam R, Wicherts DA, de Haas RJ et al (2008) Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality? J Clin Oncol 26:1635–1641CrossRefPubMedGoogle Scholar
  77. 77.
    Elias D, Youssef O, Sideris L et al (2004) Evolution of Missing Colorectal Liver Metastases Following Inductive Chemotherapy and Hepatectomy. J Surg Oncol 86:4–9CrossRefPubMedGoogle Scholar
  78. 78.
    Elias D, Goere D, Boige V et al (2007) Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin. Ann Surg Oncol 14:3188–3194CrossRefPubMedGoogle Scholar
  79. 79.
    Benoist S, Brouquet A, Penna C et al (2006) Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure? J Clin Oncol 24:3939–3945CrossRefPubMedGoogle Scholar
  80. 80.
    Tanaka K, Takakura H, Takeda K et al (2009) Importance of Complete Pathologic Response to Prehepatectomy Chemotherapy in Treating Colorectal Cancer Metastases Ann Surg 250:935–942CrossRefPubMedGoogle Scholar
  81. 81.
    Auer RC, White R, Kemeny NE et al (2010) Predictors of a True Complete Response Among Disappearing Liver Metastases From Colorectal Cancer After Chemotherapy. Cancer 116:1502–1509CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2011

Authors and Affiliations

  • Massimo Aglietta
    • 1
  1. 1.Medical Oncology, University of Turin, Division of Medical OncologyInstitute for Cancer Research and TreatmentCandiolo (TO)Italy

Personalised recommendations